Table 1.

Baseline patient characteristics in the study group as a whole (overall) and according to age and diagnosis group

CharacteristicOverall
(N=30)Children
(n=10)Adults
(n=20)MCD/MesGN
(n=22)FSGS
(n=8)
Demographics
 Age (yr)22.7 (13.6–43.0)11.7 (9.5–13.6)34.3 (22.7–47.4)22.7 (13.6–43.0)21.6 (14.2–46.1)
 Male sex15 (50)5 (50)10 (50)11 (50)4 (50)
 Caucasian29 (96.7)10 (100)19 (95)21 (95.5)8 (100)
 Smoker8 (26.7)08 (40)6 (27.3)2 (25)
Disease characteristics
 Age at onset of nephropathy6.5 (2.8–33.4)3.1 (2.2–5.7)20.6 (4.3–39.8)6.5 (2.8–23.1)7.2 (2.6–36.4)
 <18-yrs-old at onset18 (60)10 (100)8 (40)13 (59)5 (63)
 Duration of disease (years)8.5 (4.6–15.4)7.1 (6.1–10.4)10.3 (3.4–20.0)7.7 (4.6–15.4)10.3 (5.1–15.9)
 Steroid-dependent NS versus frequently relapsing NS25 versus 510 versus 015 versus 518 versus 47 versus 1
 MCD/MesGN versus FSGS7 versus 315 versus 5
 Children versus adults7 versus 153 versus 5
 Age at onset (<18 yr)18 (60)10 (100)8 (40)13 (59)5 (63)
Previous immunosuppressive treatments
 Oral steroids30 (100)10 (100)20 (100)22 (100)8 (100)
 Calcineurin inhibitors18 (60.0)9 (90.0)9 (45.0)11 (50.0)7 (87.5)
  Cyclosporine18 (60)9 (90)9 (45)11 (50)7 (87.5)
  Tacrolimus2 (6.7)2 (20)002 (25)
 Antiproliferative or cytotoxic agents17 (56.7)8 (80.0)9 (45.0)12 (54.5)5 (62.5)
  Azathioprine4 (13.3)3 (30)1 (5)3 (13.6)1 (12.5)
  Cyclophosphamide11 (36.7)4 (40)7 (35)8 (36.4)3 (37.5)
  Mofetil mycophenolate16 (53.3)7 (70)911 (50)5 (62.5)
At least one steroid-sparing agent during the past25 (83.3)10 (100)15 (75)17 (77.3)8 (100)
  • Data are presented as the median (IQR) or n (%).